Introduction
Traumatic brain injury (TBI) is a common problem in the United States, affecting more than 1.5 million individuals each year [1, 2] . Injury-event related cognitive impairments, including loss of consciousness, attention and memory impairments, and/or other alterations of consciousness, are typical manifestations of biomechanically-induced alterations of brain function. They are so common that they are embedded in most clinical case definitions of TBI [3] [4] [5] [6] . In the subacute and late post-injury periods after severe TBI, impairments of attention, processing speed, episodic memory, and executive function are common [7••] . After moderate TBI, processing speed, episodic memory, and executive function also are commonly affected in both the early and late post-injury periods. Fortunately, long-term cognitive impairments of these types are not universal nor are deficits in these domains uniform within or across individuals with such injuries [8] . When such long-term impairments occur, however, they contribute to disability [9, 10] and often are distressing to the person with TBI and his or her family [11] .
Most individuals who sustain mild TBI recover fully and do not experience long-term cognitive impairments [7••, 12, 13] . However, a non-trivial minority of these individuals develop persistent cognitive complaints and/or impairments [14] , the nature and etiology of which are subjects of considerable controversy [7••, 15] . In some cases, comorbid neuropsychiatric conditions, substance use disorders, medical conditions, medications, pre-injury factors (including neurodevelopmental conditions and neurogenetics), and post-injury psychosocial issues (including litigation) may contribute to the development and persistence of cognitive complaints and/or impairments [12, 13] . Other patients may experience long-term cognitive problems that are misattributed to mild TBI when in fact the index injury is more than mild [16] [17] [18] or preceded by prior TBI that conferred vulnerability to adverse cognitive outcomes [19] . There also may be a small subset of individuals for whom other conditions are not explanatory and whose long-term cognitive impairments reflect neurotrauma-induced disruptions of brain structure and function [20] .
Prior to initiating treatment specifically targeting post-traumatic cognitive impairments, a comprehensive neuropsychiatric evaluation is needed to: (a) establish that an injury occurred that meets the widelyaccepted definition of TBI [3] ; and (b) to determine whether cognitive difficulties experienced in the postinjury period are best accounted for by TBI, another neuropsychiatric condition, iatrogenic factors (including prescribed medications), or some combination of these and other factors. Identifying and treating comorbid neuropsychiatric conditions is essential. Additionally, estimating pre-injury cognitive function, premorbid neuropsychiatric health, the role of TBI in symptom development, the effects of bodily injuries on cognitive and psychological function, the psychosocial context in which the recovery occurred, and the effects (or lack) of any treatments provided must be ascertained. It is imperative that clinicians attend to more than superficially compelling temporal relationships when evaluating persons with post-traumatic cognitive impairments. When interpreting injury history and current symptoms, care must be taken to avoid the logical fallacies of post hoc ergo propter hoc (after TBI, therefore because of TBI) or post hoc ergo cum hoc (with TBI, therefore because of TBI) in order to ensure that opportunities to identify and treat other causes of cognitive complaints and/or impairments are not missed.
The evidence base for nonpharmacologic and pharmacologic treatments has developed substantially over the last 20 years, and especially in the last decade [21, 22, 23••, 24-37, 38•, 39•, 40•] . Although there are no United States Food and Drug Administration (FDA) approved treatments for cognitive impairments due to TBI, the published literature provides a useful guide to the treatment of such problems. Where evidence for the treatment of a specific type of post-traumatic cognitive impairment is lacking, modeling treatment after phenomenologically similar but etiologically distinct conditions (e.g., stroke, multiple sclerosis, neurodegenerative disorders, attention deficit hyperactivity disorder) may also be useful. The limitations of such treatments-by-analogy necessitate a measure of caution when prescribing medications or offering rehabilitative interventions to persons with post-traumatic cognitive impairments, especially with respect to treatment tolerability, safety, and cost-effectiveness. Nonetheless, clinicians are better positioned today to offer potentially useful treatments to individuals with these problems than at any time in the past.
The current treatment options described in this article are of two general types: cognitive rehabilitation and pharmacotherapy. Consistent with the citation style and clinical practice-oriented focus of this journal, evidence-based reviews, systematic reviews, meta-analyses, and other synthetic works are cited here where they serve to establish the evidence class associated with the treatment described and/or when they summarize large numbers of case reports, case series, uncontrolled studies, and expert opinions. Among those cited, a few recent articles of particular importance also are identified. Other interventions (e.g., edu c a t i o n a n d c o u n s e l i n g , t e c h n o l o g y -b a s e d interventions) are not addressed at length; interested readers are referred elsewhere [41, 42] for detailed reviews of these subjects. and European Federation of Neurological Societies [25, 26] performed systematic review and analysis of the cognitive rehabilitation literature for the purpose of developing evidence-based recommendations for the treatment of cognitively-impaired persons with TBI or stroke. Their recommendations include Practice Standards (based on one or more Class I studies with support from additional Class II or III studies), Practice Guidelines (based on one or more Class I studies with methodological limitations or one or more welldesigned Class II studies), and Practice Options (based on one or more Class II, III, or IV studies). These practice recommendations correspond closely to the Class I, Class II-III, and Class IV evidence ratings used in this journal, and will be translated as such in this article. Additionally, only those interventions relevant to the cognitive rehabilitation of persons with TBI are presented. & The cost-effectiveness of these treatments is not established.
Treatment

General cognitive rehabilitation interventions
Comprehensive-holistic neuropsychological rehabilitation is recommended during post-acute rehabilitation to reduce cognitive and functional disability for persons with moderate to severe TBI ( [23••] , Class I). This treatment approach encompasses cognitive rehabilitation, discipline-specific therapies (physical, occupational, and speech therapies), as well as individual and group therapies directed at metacognitive, emotional, interpersonal, and functional skills. 
Attention
There is insufficient evidence to establish that attention training provided during the acute recovery period provides benefits above and beyond those associated with spontaneous recovery alone or from more general cognitive rehabilitation interventions. Accordingly, attention training during the early post-injury period is not recommended ( [23••, 26] , Class IV). Direct attention training and metacognitive training targeting the development of compensatory strategies is recommended during the postacute rehabilitation period. Direct attentional training may improve complex attention and reduce emotional distress ( [43, 44] , Class I). Repetition of working memory tasks may also improve attention benefits ( [45] , Class IV). Clinician-guided computer-based attention training may be used as an adjunct to other cognitive rehabilitation interventions for attention. However, this adjunctive strategy should not consist solely of repeated exposure to computer-based training tasks ([23••], Class II).
Memory
Compensatory strategy training, including internalized strategy training (e.g., visual imagery) and external memory compensations (e.g., memory notebooks), is a useful treatment for post-traumatic memory impairments generally ( [23••] , Class I; [26] , Class II). Individuals with relatively mild memory impairments, relatively preserved functional independence, and sufficient motivation to engage in and rehearse these compensatory strategies are most likely to benefit from this type of intervention ([21, Language and communication 
Executive function
Metacognitive strategy training entails treatments directed at improving self-monitoring and self-regulation, including emotional selfregulation. These inventions emphasize internalizing control of the skill to be learned. This can be accomplished by structured and repetitive cueing, or by encouraging ongoing self-monitoring and assessment. Such interventions typically require a high degree of individualization to the subject, his or her strengths and deficits, and the context in which those deficits occur. Patients with relatively mild to moderate impairments in executive function are likely to benefit most from this form of cognitive rehabilitation. Awareness-training, incorporating feedback to increase the patient's appreciation for intact abilities and exercises involving predicting, self-monitoring, and self-evaluating performance, may improve self-awareness as well as cognitive aspects of instrumental activities of daily living performance ( [51, 52] , Class I). Patients with severely impaired executive function may need substantial, ongoing external interventions to compensate for such problems in even a limited fashion ( [53, 54] , Class IV). Programmatic interventions for problem-solving deficits (focused training on problem-solving strategies) during the post-acute rehabilitation period may improve function, especially when strategy training is directed at personally relevant everyday situations and functional activities ( [55, 56] 
Uncompetitive N-Methyl-D-Aspartate receptor antagonists
Amantadine
Amantadine and memantine belong to the adamantanamine group of compounds. Their principal mechanism of action is uncompetitive antagonism at the NMDA receptor complex through the phencyclidine binding site inside the receptor-associated ion channel. Antagonism of glutamatergic inhibitory inputs on presynaptic dopaminergic neurons secondarily enhances dopaminergic neurotransmission. These agents also are purported to have multiple additional effects on dopaminergic neurotransmission, including enhanced dopamine release, decreased presynaptic dopamine reuptake, stimulation of dopamine receptors, and/or enhanced postsynaptic dopamine receptor sensitivity. However, the strengths and relative contributions of direct dopaminergic modulatory properties on the clinical effects produced by amantadine and memantine when prescribed at typical doses (see below) remain uncertain [36, 58] . Treatment with amantadine within the first few days following TBI improves arousal at one week post-injury ( [39•, 59 ], Class IV). This clinical effect appears more likely to reflect its attenuation of traumatically-induced glutamate excitotoxicity during the early post-injury period than facilitation of dopamine release, since functionally disruptive excesses of cerebral dopamine are characteristic of the early post-injury neurochemical disturbances incited by biomechanical neurotrauma [36, 60, 61] . By contrast, amantadine-mediated improvements in the rate of cognitive recovery during the subacute post-injury period following TBI ( [62] , Class I) as well as accelerated rate of functional recovery during subacute treatment of post-traumatic disorders of consciousness ( [63] , Class I) most likely reflect the indirect and/or direct dopamine-facilitating effects of this medication. Similarly, these effects are most likely to account for the beneficial effects of amantadine on attention, visuospatial function (constructional praxis), executive function, and general cognitive function during the subacute and late post-injury periods following moderate to severe TBI ( [35] , Class IV).
Standard dosage 25-200 mg twice daily (total daily dose not to exceed 400 mg per day).
Contraindications Use during pregnancy and breastfeeding are contraindicated. Patients with a history of seizures should be carefully monitored for changes in seizure activity. Patients with congestive heart failure also require careful monitoring.
Main drug interactions
Amantadine may potentiate the effects of anticholinergic agents and other psychostimulants. Triamterene/hydrochlorothiazide may decrease renal excretion of amantadine.
Main side effects Headache, nausea, diarrhea, constipation, anorexia, dizziness, lightheadedness, orthostatic hypotension, anxiety, irritability, depression, and hallucinations may occur during amantadine treatment. Psychosis and confusion may occur with high doses. Abrupt withdrawal has been associated (rarely) with neuroleptic malignant syndrome.
Cost 100 mg=$1.78 ea.
Catecholamine augmentation
Methylphenidate
Methylphenidate, like dextroamphetamine and other mixed amphetamine salts, augments cerebral levels of dopamine and norepinephrine via promotion of their release and, at higher doses, blocks monoamine reuptake and confers a modest degree of monoamine oxidase inhibition. Although dextroamphetamine [64, 65] and other mixed amphetamine salts are sometimes used to treat post-traumatic cognitive impairments, the literature describing the efficacy, tolerability, and safety of methylphenidate for this purpose is much more fully developed. Accordingly, when a stimulant is used in this population, methylphenidate is the first-line medication from this class [36] . During the subacute and late post-injury periods, methylphenidate may improve hypoarousal ( [28] , Class I), attention and processing speed ( [29, 31] , Class I; [35] , Class II), and general cognitive function ( [35] , Class IV). Methylphenidate also appears to improve cognitive function and to reduce daytime sleepiness in the context of depression during the subacute period following TBI, and is comparably effective to sertraline as an antidepressant ( [66] , Class II).
Standard dosage Treatment typically begins at 5 mg twice daily, with doses given in the morning and midday. Doses are increased by 5 mg at twice-daily increments every 2-3 days, as tolerated, to a target dose of 0.3 mg per kg twice daily (e.g., for a 70 kg patient, dosing is approximately 20 mg twice daily).
Contraindications Concomitant use of an MAOI, or during pregnancy and breastfeeding should be avoided, as methylphenidate may exacerbate anxiety, psychosis, Tourette's syndrome and other tics or dyskinetic movements, glaucoma, hypertension, cardiovascular problems, and symptomatic hyperthryoidism.
Main drug interactions Methylphenidate may decrease the metabolism of tricylic antidepressants, warfarin, primidone, phenytoin, phenobarbital, and phenylbutazone, and may decrease the effectiveness of antihypertensive agents.
Main side effects Anxiety, irritability, insomnia, and dysphoria are common; methylphenidate may also suppress appetite, and cause mild increases in heart rate and blood pressure.
Special considerations Methylphenidate does not predictably lower seizure threshold among TBI patients with seizures ( [27, 32] , Class I; [67] , Class IV) and appears to be a generally safe treatment in this population ( [27, 32] , Class I).
Cost 5 mg=$0.33 ea.; 10 mg=$0.47 ea.; 20 mg=$0.68 ea.
Bromocriptine
Bromocriptine acts directly on dopamine type 2 (D2) receptors. At low doses, bromocriptine acts as a presynaptic D2 receptor agonist, thereby reducing dopaminergic release and the function of dopaminergically-dependent neural systems. At mid-range doses, postsynaptic effects at D2 receptors predominate and, on balance, bromocriptine augments the function of the neural networks in which dopamine-responsive neurons participate [36] .
In the subacute and late periods following complicated mild to severe TBI, bromocriptine improves executive function ( [68] , Class I). It may also improve "cognitive initiation" (i.e., diminished motivation, or apathy) in the late post-injury period ( [69, 70] , Class IV). Bromocriptine does not appear to improve working memory ( [68] , Class I) or attention ( [30] , Class I) during the subacute or late periods following TBI, and its administration in this context is associated with clinically concerning adverse effects ( [30] , Class I). The effects of bromocriptine on arousal among persons with disorders of consciousness are inconsistent ( [70, 71] , Class IV). In light of the evidence favoring amantadine for this purpose ( [63] , Class I), bromocriptine is at best a second-line intervention for the treatment of posttraumatic disorders of consciousness.
Standard dosage 2.5-7.5 mg twice daily; package insert suggests that bromocriptine may be administered safely up to doses of 100 mg daily, although safety of such dosing among persons with TBI is not established.
Contraindications Uncontrolled hypertension and hypersensitivity to ergot alkaloids are strict contraindications. Although breastfeeding is contraindicated, use during pregnancy does not appear to be associated with significant increased adverse events or outcomes.
Main drug interactions Bromocriptine decreases the effectiveness of antidopaminergic agents.
Main side effects Dizziness, drowsiness, faintness, syncope, nausea, vomiting, abdominal cramps, constipation, and diarrhea may occur frequently, though they are generally of mild severity.
Cholinergic augmentation
Treatment with cholinesterase inhibitors may contribute usefully to the treatment of persons with post-traumatic memory impairments during the subacute and late post-injury periods [35, 36, 38•, 40•, 61] . Although physostigmine has been used for this purpose [72] , newer and better-tolerated cholinesterase inhibitors have supplanted it as a cholinergically-augmenting pharmacotherapy for post-traumatic cognitive impairments.
Donepezil
Donepezil is a centrally-selective acetylcholinesterase inhibitor. Treatment with donepezil improves attention and memory impairments during the subacute post-injury period ( [33] , Class I). In the late postinjury period, donepezil may improve subjective attention and memory complaints ( [20] , Class II; [73] , Class IV), sensory gating impairments ( [20] , Class II), declarative memory impairments ( [35, 40•] , Class III), and related neurobehavioral disturbances ( [73, 74] , Class IV).
Standard dosage 5-10 mg daily.
Contraindications Known hypersensitivity to donepezil or piperidine derivatives, pregnancy, and breastfeeding.
Main drug interactions Agents that inhibit hepatic metabolism (CYP450, 3A4, and 2D6) such as ketoconazole and quinidine may increase blood levels of donepezil. Inducers of hepatic metabolism (phenobarbital, phenytoin, carbamazepine, dexamethasone, rifampin) may decrease blood levels. However, little is presently known about the drug-drug interactions of this agent.
Main side effects Headache, nausea, diarrhea, vomiting, fatigue, insomnia, muscle cramping, pain, and abnormal dreams.
Cost 5 mg=$7.87 ea.
Rivastigmine
Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase; the former provides its mechanism of action on cerebral cholinergic function. Treatment with rivastigmine in the late post-injury period may improve attention and working memory ( [75] , Class I), although this effect was not observed in a similarly large study of this population ( [34] , Class I). In a planned secondary analysis of persons with persistent posttraumatic memory impairments, rivastigmine improved declarative memory and secondarily improved attention, processing speed, executive function, and neuropsychiatric status ( [34] , Class II; [37] , Class IV). Subjective improvements in attention, memory, motivation, and fatigue also are reported ( [73] , Class IV).
Standard dosage 1.5-6 mg twice daily.
Contraindications Known hypersensitivity to carbamates, pregnancy, and breastfeeding.
Main drug interactions Rivastigmine may increase the effects of anesthetics and should be discontinued prior to surgery. Bradycardia may occur if combined with beta-blockers. Potential synergistic effects if co-administered with cholinomimetics.
Main side effects Headache, nausea, diarrhea, vomiting, fatigue, appetite loss, dizziness, asthenia, sweating.
Cost 3 mg=$2.50 ea.
Mixed catecholamine and cholinergic augmentation
Cytidine 5'-diphosphocholine (citicoline)
Cytidine 5'-diphosphocholine (citicoline, or CDP-choline) is an essential intermediate in the biosynthetic pathway of phospholipids incorporated into cell membranes. It appears to activate the biosynthesis of structural phospholipids in neuronal membranes, increase cerebral metabolism, and enhance activity of dopamine, norepinephrine, and acetylcholine ( [76] [77] [78] ). Treatment with citicoline during the early period after mild to moderate TBI may reduce postconcussive symptoms and improve recognition memory ( [79] , Class I). Among persons with moderate to severe TBI receiving inpatient rehabilitation, citicoline improves cognitive, motor, and psychiatric disturbances and shortens length of stay ( [80] , Class I).
Standard dosage Up to 1-2 grams daily.
Contraindications There are no known contraindications; given the limited available data, use during pregnancy or when breastfeeding is discouraged.
Main drug interactions There are no known drug interactions with citicoline.
Main side effects Side effects are uncommon, but may include insomnia, blurred vision, headache, nausea, diarrhea, blood pressure alterations, and chest pain.
Cost 250 mg=$0.67 ea.
Additional medication considerations
& Patients with TBI are particularly susceptible to the adverse cognitive effects of antipsychotic medications ( [36, 38•, 60] , Class IV). In general, these effects remit upon discontinuation of these agents. & Antiepileptic drugs may contribute to cognitive impairment subsequent to TBI ( [35, 36, 81] , Class IV). Prophylactic treatment with phenytoin ( [82, 83] , Class I) or carbamazepine ( [83] , Class I) after the first week post-injury produces cognitive impairments. Valproate appears to be cognitively neutral during this period and may be preferable when either continued prophylaxis or treatment of posttraumatic seizures is required ( [84] , Class I). & Benzodiazepines as well as atypical gamma-aminobutyric acid (GABA) agonists may exacerbate cognitive disturbances in TBI patients ( [64] , Class III; [85] , Class IV). Additionally, GABA agonists may negatively impact neuroplasticity, arguing against their use during the acute recovery period [85] . & Medications with anticholinergic properties may produce cognitive impairments (especially memory, attention, and executive function disturbances) at doses that are likely to be innocuous among persons without TBI ( [61] , Class IV).
Education
& Early education and counseling regarding TBI, postconcussive symptoms, expected course and typical outcomes are among the most effective interventions with which to reduce the risk of atypical recovery and persistent postconcussive symptoms after mild TBI ( [86, 87] , Class I), as well as moderate to severe TBI ( [88] , Class I).
